Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

Research reported in this publication was supported through the Geisel School of Medicine at Dartmouth’s Center for Quantitative Biology through a grant from the NIGMS Award P20GM130454, an NIH S10 (S10OD025235) grant, and funding from The Elmer R Pfefferkorn & Allan U Munck Education and Research Fund at Dartmouth (D Pattabiraman). This work was supported by funding from METAvivor (D Pattabiraman) and NIH (R00CA201574 [D Pattabiraman], R01CA267691 [D Pattabiraman and T Miller] and R01CA216265, R01CA253976 [B Christensen]). This study received partial support through a Sponsored Research Agreement from Eisai, Inc. to D Pattabiraman; the authors and Eisai, Inc. declare no competing interests related to this study. B Christensen is an advisor to Guardant Health, which had no role in this research. All other authors report that they have no conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Comments (0)

No login
gif